Medivir AB (STO: MVIRB), a medical research company, reported on Wednesday a negative earnings per diluted share of SEK3.88 for the second quarter of 2018, from April 2018 to June 201.

This was an improvement over a negative EPS of SEK3.91 per diluted share, in Q2 2017.

Loss before interest, tax, depreciation and amortisation (EBITDA) for the quarter totaled a negative SEK89.9m, an improvement over a negative SEK90.9m, in Q2 2017.

Net turnover for the quarter totalled SEK2.8m, as compared with SEK9.5m in Q2 2017.

Medivir develops new drugs and pharmaceutical compounds based on proteases and polymerases as target enzymes. Medivir focuses on infectious and immunological diseases including projects against HIV, jaundice, shingles, multiple sclerosis and rheumatoid arthritis.

(EUR1.00=SEK10.26)